
**WHAT IS CLAIMED IS:**

1. A liquid oral pharmaceutical composition comprising a compound of formula (***II***):



(***II***)

or a crystalline form thereof, wherein the pharmaceutical composition comprises 0.10% to 2% w/w of the compound of formula (***II***), or a crystalline form thereof; 0.20% to 3% w/w of sodium bicarbonate; and 50% to 99.2% w/w of a solvent mixture comprising propylene glycol, purified water, and PEG400; wherein the composition contains 15% to 30% w/w propylene glycol and 15% to 30% w/w PEG400.

2. The pharmaceutical composition of claim 1, wherein the solvent mixture further comprises glycerin .

3. The pharmaceutical composition of claim 1 or 2, wherein the purified water is present in an amount of 9.11% to 38.41% w/w.

4. The pharmaceutical composition of any one of claims 1 to 3, wherein the compound of formula (***II***) is present in an amount of 0.40 % w/w to 0.50 % w/w.

5. The pharmaceutical composition of any one of claims 1 to 3, wherein the solvent is present in an amount of 97%, 98% or 99 % w/w.

6. The pharmaceutical composition of any one of claims 1 to 3, wherein the solvent is present in an amount of 68%, 69% or 70 % w/w.

7. The pharmaceutical composition of any one of claims 1 to 3, wherein the solvent is a mixture of propylene glycol, glycerin, PEG400, and purified water.

8. The pharmaceutical composition of any one of claims 1 to 3, wherein the solvent is a mixture of PEG400, propylene glycol, and purified water.

9. The pharmaceutical composition of any one of claims 1 to 3, wherein the sodium bicarbonate is present in an amount of 0.42 % w/w.

10. The pharmaceutical composition of any one of claims 1 to 3, further comprising a preservative present in an amount of no more than 1% w/w, wherein the preservative is selected from the group consisting of methylparaben, propylparaben, and mixtures thereof.

11. The pharmaceutical composition of any one of claims 1 to 3, further comprising a surfactant present in an amount of no more than 1% w/w, wherein the surfactant is sodium lauryl sulfate.

12. The pharmaceutical composition of any one of claims 1 to 3, further comprising a taste-masking agent, wherein the taste-masking agent is selected from the group consisting of sorbitol, maltitol, sucrose, acesulfame potassium and mixtures thereof.


13. The pharmaceutical composition of claim 12, wherein the taste-masking agent is sorbitol.

14. The pharmaceutical composition of claim 10, wherein the preservative is present in an amount of 0.2 % w/w.

15. The pharmaceutical composition of claim 11, wherein the surfactant is present in an amount of 0.5 % w/w.

16. The pharmaceutical composition of claim 12, wherein the taste-masking agent is acesulfame potassium.

17. A liquid oral pharmaceutical composition comprising a compound of formula (***II***):




(***II***)


or a crystalline form thereof, wherein the pharmaceutical composition comprises the compound of formula (***II***) in an amount of 0.40% w/w to 0.50% w/w, sodium bicarbonate in an amount of 0.42% w/w, and 50% to 99.2% w/w of a solvent mixture comprising propylene glycol, purified water, and PEG400; wherein the composition contains 15% to 30% w/w propylene glycol and 15% to 30% w/w PEG400.

18. The pharmaceutical composition of claim 17, wherein the solvent mixture further comprises glycerin.

19. The pharmaceutical composition of claims 17 or 18, wherein the purified water is present in an amount of 9.11% to 38.41% w/w.

20. The pharmaceutical composition of any one of claims 17-19, further comprising a taste-masking agent.

21. A liquid oral pharmaceutical composition comprising a compound of formula (***II***):




(***II***)

or a crystalline form thereof, wherein the pharmaceutical composition comprises the compound of formula (***II***) in an amount of 0.40% w/w to 0.50% w/w; sodium bicarbonate in an amount of 0.42% w/w; acesulfame potassium; a flavoring agent; and solvent in an amount of 97%, 98%, or 99% w/w, wherein the solvent is a mixture of propylene glycol, glycerin, PEG400, and purified water, and wherein the composition contains 15% to 30% w/w propylene glycol and 15% to 30% w/w PEG400.

22. The pharmaceutical composition of claim 21, wherein the purified water is present in an amount of 9.11% to 38.41% w/w.

23. A liquid oral pharmaceutical composition comprising a compound of formula (***II***):



(***II***)

or a crystalline form thereof, wherein the pharmaceutical composition comprises the compound of formula (***II***) in an amount of 0.40% w/w to 0.50% w/w; sodium bicarbonate in an amount of 0.42% w/w; sorbitol; and solvent in an amount of 68%, 69%, or 70% w/w, wherein the solvent is a mixture of propylene glycol, PEG400, and purified water, and wherein the composition contains 15% to 30% w/w propylene glycol and 15% to 30% w/w PEG400.

24. The pharmaceutical composition of claim 23, wherein the purified water is present in an amount of 9.11% to 38.41% w/w.

25. Use of the pharmaceutical composition of any one of claims 1-8, 9, 10, 11, 12, 13, and 14-24 in the manufacture of a medicament for the treatment of cancer.

26. The use of claim 25, wherein the cancer is selected from the group consisting of colorectal cancer, ovarian cancer, breast cancer, lung cancer, gastric cancer, prostate cancer, pancreatic cancer, neuroblastoma, and acute lymphoblastic leukemia.

27. The use of claim 25, wherein the cancer is lung cancer.

28. The pharmaceutical composition of any one of claims 1-8, 9, 10, 11, 12, 13, and 14-24 for use in the treatment of cancer.

29. The pharmaceutical composition of claim 28, wherein the cancer is selected from the group consisting of colorectal cancer, ovarian cancer, breast cancer, lung cancer, gastric cancer, prostate cancer, pancreatic cancer, neuroblastoma, and acute lymphoblastic leukemia.

30. The pharmaceutical composition of claim 28, wherein the cancer is lung cancer.